Manage your formulary budget
Anticipate generic drug launch
Find generic entry opportunities
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Anticonvulsant sulfamate derivatives|
|Abstract:||Sulfamates of the following formula (I): ##STR1## wherein X is O or CH.sub.2 and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as herein defined have been found to exhibit anticonvulsant activity and are thus useful in the treatment of conditions such as epilepsy. Further, pharmaceutical compositions containing a compound of formula (I) as well as methods for their use and intermediates form part of the present invention.|
|Inventor(s):||Maryanoff; Bruce E. (New Hope, PA), Gardocki; Joseph F. (Doylestown, PA)|
|Assignee:||McNeil Lab., Inc. (Fort Washington, PA)|
1. A sulfamate of the following formula (I): ##STR11## wherein X is oxygen;
R.sub.1 is hydrogen or alkyl; and
R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently hydrogen or lower alkyl and R.sub.2 and R.sub.3 and/or R.sub.4 and R.sub.5 together may be a group of the following formula (II): ##STR12## wherein R.sub.6 and R.sub.7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
2. The sulfamate of claim 1, wherein
R.sub.2 and R.sub.3 and R.sub.4 and R.sub.5 together are groups of the formula (II).
3. The sulfamate of claim 1, wherein said alkyl group for R.sub.1 is alkyl of about 1 to 4 carbons; said lower alkyl group for R.sub.2, R.sub.3, R.sub.4 and R.sub.5 is alkyl of about 1 to 3 carbons; and said lower alkyl for R.sub.6 and R.sub.7 is alkyl of about 1 to 3 carbons.
4. The sulfamate of claim 1, wherein said sulfamate of formula (I) is selected from the group consisting of:
5. The sulfamate of claim 4, wherein said sulfamate is 2,3:4,5-bis-O-(1-methylethylidene)-.beta.-D-fructopyranose sulfamate.
6. A pharmaceutical composition effective for the treatment of convulsions comprising an anticonvulsantly effective amount of a sulfamate of claim 1 and a pharmaceutically-acceptable carrier.
7. The pharmaceutical composition of claim 6, wherein said sulfamate is present in a unit dosage amount of about 10 to 500 milligrams of the sulfamate.
8. A method for the treatment of convulsions in a mammal which comprises administering to the mammal, the pharmaceutical composition of claim 6.
9. The sulfamate of claim 4, wherein said sulfamate is
10. The sulfamate of claim 1, wherein the two oxygen atoms of the group of formula (II) are attached on the same side of the six-membered ring depicted in formula (I).
11. The sulfamate of claim 1, wherein the sulfamate of formula (I) is a fructopyranose.
12. The sulfamate of claim 1, wherein in formula (I), R.sub.1 is hydrogen.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.